Published in final edited form as:

Pharmacogenet Genomics. 2015 April ; 25(4): 205–221. doi:10.1097/FPC.0000000000000118.

PharmGKB Summary: Very Important Pharmacogene Information for Human Leukocyte Antigen B (HLA-B)

Julia M. Barbarino, M.Sc.^a, Deanna L. Kroetz, Ph.D.^b, Teri E. Klein, Ph.D.^a, and Russ B. Altman, M.D., Ph.D.^{a,c}

^aDepartment of Genetics, University of California San Francisco, California, USA.

^bDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, California, USA.

^cDepartment of Bioengineering, Stanford University, California, USA.

Keywords

Abacavir; allopurinol; carbamazepine; *HLA-B*; *HLA-B*15:02*; *HLA-B*57:01*; *HLA-B*58:01*; pharmacogenetics; PharmGKB; phenytoin

Introduction

The human leukocyte antigen B (HLA-B) gene is a member of the major histocompatibility complex (MHC), a region of the human genome located on chromosome 6. The MHC (also known as the human leukocyte antigen (HLA) complex) includes three subregions, designated as class I, class II and class III. Each of these subregions contains a variety of genes that mainly code for proteins involved in the immune system. *HLA-B* is part of the class I group, along with *HLA-A* and *HLA-C*, all three of which code for their eponymous proteins [1]. Class II genes include *HLA-DR*, *HLA-DP* and *HLA-DQ* [2], and class III genes include complement components and cytokines such as complement factor B (*CFB*) and members of the tumor necrosis factor (*TNF*) family [1, 3]. The MHC is a large region of the genome, and contains many other genes besides the ones listed above; please see Horton *et al.* [1] for more details. The *HLA* genes are important within the field of pharmacogenetics: variations within these genes have been associated with severe drug reactions, as well as changes in how well a patient responds to a drug.

The HLA-B protein and the other class I group members are cell-surface molecules responsible for the presentation of endogenous peptides to CD8+ T-cells, and exist on almost all nucleated cells. This is in contrast to class II molecules, which display exogenous peptides to CD4+ T-cells, and are present only on antigen presenting cells (APCs) such as macrophages or dendritic cells [2, 4]. This presentation of peptides to T-cells assists in the

Correspondence to Dr. Teri E. Klein, Ph.D., Department of Genetics, Stanford School of Medicine, Shriram Center for BioE & ChemE, 443 Via Ortega, Room 213, Stanford, CA 94305, USA Tel: +1 650 736 0156; fax: +1 650 725 3863; teri.klein@stanford.edu.

Conflicts of Interest

RBA and TEK are stockholders in Personalis Inc.

recognition of pathogens [2]. As a class I molecule, most of the peptides that HLA-B presents come from the normal breakdown of host cellular proteins, and are recognized by the immune system as such (i.e. “self” peptides). However, when a cell becomes infected by a pathogen, the proteins presented will be from the pathogen and recognized as foreign or “non-self”. T cell antigen receptors (TCRs) on CD8+ cytotoxic T cells are responsible for this recognition, and will stimulate an immune reaction that destroys the cell [5].

Class I molecules are expressed in a codominant fashion, and humans inherit a set of *HLA-A*, *B* and *C* genes from each parent. Therefore, given allelic variations within these genes, up to six different class I molecules can be expressed on a cell surface. HLA-A, B and C are heterodimers consisting of an α chain, encoded by their respective genes, and a protein known as β 2-microglobulin, which is encoded on chromosome 15. The α chain of HLA-B has four domains: one cytoplasmic, one transmembrane, one which binds to CD8+ cytotoxic T cells, and one which makes up a peptide-binding groove, where the presented peptide is nestled [5]. This peptide-binding region of the gene is highly polymorphic, and allelic differences between class I genes are often due to variations within this region [2, 5]. Indeed, allelic variants of class I genes can differ from one another by up to 20 amino acids. Peptides bind to the groove through interaction with specific amino acid residues, so any amino acid changes due to allelic variation may affect the peptide-binding specificity of a class I molecule [5] (class II molecules have more flexibility in peptide-binding; see Janeway *et al.* [5]). The type of extensive polymorphism seen in HLA genes allows a wide variety of peptides to be presented, and likely evolved in order to effectively combat pathogens [5]. In addition to affecting the peptides capable of being presented, allelic variants in the *HLA-B* gene have also been associated with susceptibility and resistance to numerous diseases, as well as adverse reactions to a wide range of pharmaceuticals. This makes *HLA-B* highly relevant to pharmacogenetic research. This Very Important Pharmacogene (VIP) summary on *HLAB* is available with interactive links to genetic variants and drugs on the PharmGKB website at <http://www.pharmgkb.org/gene/PA35056>.

***HLA-B* allele frequencies and nomenclature**

Due to the highly polymorphic nature of class I genes, a large number of *HLA-B* alleles have been identified. Information on the frequencies of over 2800 *HLA-B* alleles in populations worldwide can be found at The Allele Frequency Net Database (<http://www.allelefrequencies.net/>) [6]; allele frequencies for specific polymorphisms will be discussed within relevant sections of this review. Systematic nomenclature for these alleles is invaluable given their quantity. The HLA nomenclature committee has provided a detailed nomenclature to this end, and comprehensive information on the allele naming process can be found at their website at <http://hla.alleles.org> [7]. Briefly, all *HLA* alleles receive at least a four-digit name consisting of two sets of two digits separated by a colon, such as *HLA-B*57:01*. The first set of digits before the colon describes the type, typically the antigen designation used to describe the *HLA* alleles prior to genetic sequencing. The second set of digits indicates the specific allele, numerically ordered based on when the DNA sequence was discovered; this set of digits describes nonsynonymous substitutions only [7, 8]. This paper will only refer to the first one or two sets of digits. However, longer names, up to four sets of digits separated by colons and possibly a letter suffix, can be assigned if more detail

is necessary, such as type or location of nucleotide substitution (e.g. synonymous or intronic) or resultant protein expression (e.g. null protein or cytoplasmic protein); for more information on this process, please refer to the HLA nomenclature website (<http://hla.alleles.org>).

HLA-B and disease associations

A number of *HLA-B* alleles or allele groups have been associated with susceptibility or resistance to particular diseases. These include *HLA-B*53* and resistance to malaria [9, 10], *HLA-B*51* and susceptibility to the inflammatory condition Beçhet's disease [11, 12], and *HLA-B*46* and increased risk of Graves' disease, an autoimmune disorder [13]. Two particularly strong disease associations are *HLA-B*57* and HIV long-term non-progression, and *HLA-B*27* and ankylosing spondylitis.

HLA-B*57 and HIV long-term non-progression—Without treatment, almost all people infected with HIV will ultimately progress to AIDS. However, a small percentage of patients do not advance, even long after the median progression time. These patients are referred to as long-term non-progressors or “elite controllers”, and *HLA-B*57* alleles, particularly **57:01* and **57:03*, are highly enriched in this group of individuals [14-21]. Though this association is well known, the mechanism by which it occurs remains unclear. Košmrlj *et al.* used computer algorithms to predict that less than half the number of unique peptides (derived from the human proteome) bound to the *HLA-B*57:01* protein as compared to *HLA-B*07:01* (a non- HIV-protective form of the molecule). The authors suggested that this affected repertoire development, leading to T-cells that had been exposed to fewer self-peptides. This in turn may lead to a higher frequency of T-cells that recognize viral peptides, such as those from HIV, as well as T-cells that are more cross-reactive toward mutant epitopes. These qualities would enable the T-cells to better control the HIV infection, keeping the viral load in check and thereby making the development of AIDS unlikely [16].

HLA-B*27 and ankylosing spondylitis

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease, affecting mainly the axial skeleton and sacroiliac joints. It leads to inflammatory back pain, as well as other clinical features including enthesitis and anterior uveitis [22]. Presence of *HLA-B*27* leads to the greatest risk for AS, and this form of *HLA-B* is found in over 90% of AS patients with European ancestry. However, only 1-5% of *HLA-B*27* individuals will go on to develop AS, and not all alleles of *HLA-B*27* are associated with its development. While *HLA-B*27:05*, **27:02*, **27:04* and **27:07* do confer risk, other types such as **27:06* and **27:09* do not appear to be associated with the disease [23]. As with HIV and *HLA-B*57:01*, the mechanism behind this association is unclear, though multiple theories have attempted to explain the relationship. Several of these theories are summarized in a review by McHugh and Bowness [24], including the arthritogenic peptide hypothesis, which suggests that *HLA-B*27* binds particular peptides that give rise to a cytotoxic T-cell response, the misfolding and unfolded protein response (UPR) hypothesis, which suggests that the accumulation of abnormally folded *HLA-B*27* molecules leads to an inflammatory response, and the free heavy chain and homodimer hypothesis, where AS results from the immune recognition of monomeric or dimeric β 2-microglobulin-free and peptide-free *HLA-B*27* molecules [24].

Recent GWAS analyses have identified a number of non-MHC genes associated with AS susceptibility; these genes may help explain the mechanism of AS pathogenesis. For example, multiple genes within the interleukin-23 (IL-23) proinflammatory cytokine pathway were associated with AS, indicating that this may be a core immunological pathway underlying disease development. Additionally, multiple aminopeptidase genes, such as *ERAP1* and *ERAP2*, have been associated with AS. The protein products of these genes are involved in peptide trimming prior to HLA class I binding and presentation, suggesting that HLAB*27 may be involved in disease development through the aberrant trimming or presentation of peptides [25-28].

HLA-B pharmacogenetics

HLA-B alleles have been associated with reactions to a large number of different drugs. Some of these associations have been well studied, such as *HLA-B*57:01* and abacavir hypersensitivity, *HLA-B*58:01* and allopurinol-induced severe cutaneous adverse reactions (SCARs), and *HLA-B*15:02* and carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Other associations that are not as widely studied, but still show significant results include *HLA-B*57:01* and flucloxacillin-induced liver injury and *HLA-B*15:02* and phenytoin-induced SJS and TEN. A list of the *HLA-B* alleles and pharmacogenetic associations discussed in this review (along with their positive and negative predictive values, if available) can be seen in Table 1. For the alleles presented in this paper, there is no difference in phenotype depending on whether one or two *HLA-B* alleles are present, and therefore the pharmacogenetic studies discussed only consider whether an individual has the allele or not. Consequently, in the tables throughout this review, “prevalence” of an *HLA-B* allele refers to how many patients carry that allele, and not the frequency of the allele in the population. Some studies do use allele frequencies in their statistical analyses, and these cases are noted within the tables.

Many other *HLA-B* alleles besides the ones discussed in this paper have shown associations with various drug phenotypes. A table of all the *HLA-B* allele and drug phenotype associations currently annotated by PharmGKB can be found on the website at <http://www.pharmgkb.org/gene/PA35056>.

HLA-B Testing

Several options exist for determining whether a patient carries a particular *HLA-B* allele. One is by direct sequencing of the gene, and assignment of a star allele after checking the sequence against known *HLA-B* alleles. Though this method provides high-resolution genotyping and is the most accurate, it is both time-consuming and expensive and is not widely used [8]. An alternative and commonly used approach is genotyping, where the sequence variants known to define a particular *HLA-B* allele are detected using polymerase chain reaction (PCR) primers specific for each variant [8]. Quality assurance studies done on the accuracy of *HLA-B*57:01* testing using sequence-specific primer PCR (SSP-PCR) across multiple laboratories have shown very high sensitivity and specificity, indicating that laboratories using this method appear to be offering effective screening for the allele [29]. Another method that offers cost-effective, rapid and sensitive screening for *HLA-B*57:01* or *HLA-B*58:01* is flow cytometry. *HLA-B*57:01* and *HLA-B*58:01* belong to a serological

group known as HLA-B17. B17 monoclonal antibodies can be used to identify individuals who carry the HLA-B17 serotype, and these individuals can then undergo further DNA typing to determine whether they carry the *57:01 or *58:01 risk alleles. Since B17 is normally present in less than 10% of the population, assaying for presence of B17 first allows greater than 90% of a patient population to be eliminated from unnecessary HLA testing [30-32].

It is also possible to test for the presence of an *HLA-B* allele by genotyping for one or more single nucleotide polymorphisms (SNPs) nearby in linkage disequilibrium with that allele. However, linkage disequilibrium can vary across populations, and this method may have lower accuracy [8, 33]. The *HCP5* SNP rs2395029 has been suggested as a potential marker for abacavir-induced hypersensitivity, since the variant allele has shown strong linkage disequilibrium with *57:01 [34-37]. However, it is not in complete concordance with *57:01 [38, 39], and individuals with the *57:01 allele but not the rs2395029 variant allele [38-40] as well as individuals with the rs2395029 variant allele but not the *57:01 allele [34, 35, 38, 39] have been noted. This type of incomplete concordance could result in the denial of abacavir to individuals who are not at risk for a hypersensitivity reaction, or administration of abacavir to individuals who are at risk for a hypersensitivity reaction [8, 40]. Additionally, the studies showing strong linkage between *57:01 and rs2395029 have been conducted in populations of mainly Caucasian or Hispanic descent; the strength of the linkage between the alleles has not been confirmed in large African or Asian populations [8]. Several studies have noted that caution should be used when using rs2395029 as a surrogate marker for *HLA-B**57:01 [8, 41, 42]. However, due to the inexpensive and straightforward nature of this screening method, some laboratories do choose to perform SNP testing over allele-specific PCR [8].

It is important to note that currently, the high level of polymorphism within the *HLA* genes makes HLA genotyping at a high resolution challenging [43-45]. Present sequencing methods can result in ambiguous typing results with an inability to resolve phase [43, 44]. Additionally, different alleles may share similar sequences within the sequenced region [45], and defining polymorphisms may lie outside the amplified region [43, 44]. These issues may be resolved through next-generation sequencing (NGS), which allows for clonal amplification and massively parallel sequencing. These two properties provide phase information and the ability to sequence more and larger regions of genes, including intronic regions [43, 44].

A list of commercially available genetic tests for various *HLA-B* alleles can be found on PharmGKB at <http://www.pharmgkb.org/views/viewGeneticTests.action>; a more comprehensive list can be found at the Genetic Testing Registry (<http://www.ncbi.nlm.nih.gov/gtr/>). Since HLA-B expression is co-dominant, *HLA-B* genotyping results are either “positive”, with the * allele being present in one or both copies of the gene, or “negative”, where no copies of the allele are present; there is no intermediate phenotype [8].

Important variants

HLA-B*57:01

Abacavir—In addition to being enriched in HIV long-term non-progressors, the *57:01 allele is also strongly and independently associated with the development of an abacavir hypersensitivity reaction (HSR). Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) used for treatment of human immunodeficiency virus (HIV). It is generally well tolerated, and common side effects include nausea, headache and diarrhea [46]. However, approximately 5-8% of patients experience a HSR within the first 6 weeks of treatment [8]. Symptoms of a HSR include at least two of the following: fever, rash, cough, gastrointestinal symptoms (e.g., nausea, vomiting, abdominal pain), dyspnea and fatigue [8]. These symptoms worsen with continued treatment, but typically improve within 24 hours after discontinuation. However, drug rechallenge after discontinuation of abacavir due to a HSR can result in symptom recurrence within a matter of hours, and potentially life-threatening allergic reactions [47, 48]. An overview of abacavir and *57:01 pharmacogenetic studies can be found in Table 2.

In 2002, two separate research groups published the first evidence that *HLA-B*57:01* was present in a significantly higher percentage of patients showing an abacavir HSR compared to patients with no reaction. These studies were conducted in North American [49] and Australian [48] populations, and both included 200 participants. This association was subsequently confirmed by another study within a UK population of 64 patients [50]. However, these three studies were all conducted using predominantly Caucasian males, limiting their scope. Despite this limitation, several clinics began implementing prospective screening of these alleles with success [51-53]. A later study recognized the significance of the allele in White female and Hispanic populations, but found no significant associations for the Black population from this study [54]. This was likely due to the lower number of Black patients within the study, and the fact that Black populations tend to have a lower carriage rate of the allele [54, 55] – African populations often have *57:01 allele frequencies of less than 2.5%, in contrast to European populations, who often have *57:01 frequencies of 6 – 7% [8]. Indeed, a study in Ugandan patients failed to find the *57:01 allele in either patients with an abacavir HSR or tolerant controls [56].

In 2007, a study known as SHAPE (which included a similar number of White and Black participants) found that Black patients did have fewer cases of abacavir HSRs. However, 100% of both White and Black patients who had immunologically confirmed HSRs were positive for the *HLA-B*57:01* allele [55]. This suggested that though immunologically confirmed HSRs are rare among Black populations due to the reduced frequency of *57:01, the allele has the same clinical implications in both populations [55]. A definitive association between *57:01 and abacavir HSRs came in 2008 with the results of the PREDICT-1 study, a double-blind, prospective, randomized study with 1956 patients from 19 countries. Patients were observed for six weeks and separated into two categories: those that underwent screening for the *HLA-B*57:01* allele and were excluded from treatment with abacavir if they tested positive, and those that underwent standard care without any screening. Abacavir HSRs were immunologically confirmed with skin patch testing. The

results of the study showed that screening eliminated immunologically confirmed HSRs - 0% of the patients screened had a HSR, while 2.7% of the control population did. This gave the screening a negative predictive value of 100% [57]. The positive predictive value of *HLA-B*57:01* for abacavir-induced HSRs is typically cited as 55%, implying that around half of all patients who are *HLA-B*57:01* positive will not develop an abacavir HSR [41, 58, 59]. This indicates that other genes and environmental factors are likely involved in the development of an abacavir-induced HSR. Research in this area has been scarce, but several studies have suggested a member of the 70 kilodalton heat shock protein (HSP70) family as a potential factor [60-62].

This body of evidence led the FDA to implement a boxed warning in 2008, detailing the risk of a HSR for abacavir-treated patients with the *HLA-B*57:01* allele. The FDA also recommended that all patients be screened before being treated, and to not use abacavir in *HLA-B*57:01*-positive individuals [63]. The European Medicines Agency (EMA) [64], and therapeutic guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) [8] and the Dutch Pharmacogenetics Working Group (DPWG) [65] also recommend genotyping for this allele prior to beginning abacavir treatment.

The HLA-B protein has no direct effect on abacavir pharmacokinetics or pharmacodynamics, and it is still unclear how the *HLA-B*57:01* allele affects susceptibility to drug hypersensitivity. Several hypotheses exist. One is the hapten concept, which suggests that small compounds such as drugs (“haptens”), bind to the peptides bound to immune receptors such as HLA-B, causing T cells to react and stimulate an immune reaction [66]. Another is the p-i concept (pharmacological interactions with immune receptors), which proposes that drugs bind directly and reversibly to immune receptors, stimulating an immune reaction [66]. Recent evidence seems to support an alternative hypothesis. Two studies, both published in 2012, found that abacavir can bind non-covalently and with specificity to the F pocket of the peptide-binding groove of *HLA-B*57:01* [67, 68]. Due to the amino acid residues unique to the *57:01 protein, abacavir can bind only to this particular form of HLA-B. The binding of abacavir to *HLA-B*57:01* is believed to change the shape and chemistry of the antigen-binding cleft, and consequently the repertoire of peptides which can bind the molecule. Indeed, both of these papers, as well as an additional paper by Norcross *et al.*, all identified specific changes in the peptides presented by *HLA-B*57:01* in the presence of abacavir, as compared to *HLA-B*57:01* in the absence of the drug [67-69]. Since T cells are trained to be tolerant to a particular repertoire of peptides during their development in the thymus, the alteration in the peptides that can be presented may mean that these new peptides are perceived as foreign. This change would stimulate CD8+ T cell production and response, and would manifest as an abacavir HSR [67, 68]. Indeed, CD8+ T cells are abundant in skin biopsies of patients who present with a rash during an abacavir HSR [70].

Flucloxacillin—*HLA-B*57:01* is also associated with flucloxacillin drug-induced liver injury (DILI). Flucloxacillin is a semi-synthetic penicillin, used widely across Europe and Australia for staphylococcal infection [71, 72]. However, it is also associated with the development of cholestatic hepatitis, with risk factors being female sex, age over 55 years old and treatment duration of longer than two weeks [72]. A genome-wide association study

found that a marker in complete linkage disequilibrium with *HLA-B*57:01* was also strongly associated with flucloxacillin DILI. Further analysis found that patients with this allele had a 80-fold increased risk of developing DILI, as compared to those without the allele [71]. However, flucloxacillin DILI is a very rare condition, with an estimated prevalence of only 8.5 out of every 100,000 patients. Additionally, the positive predictive value of **57:01* for DILI is only 0.12%, meaning that the majority of patients with **57:01* will not develop flucloxacillin-induced DILI. Indeed, this positive predictive value indicates that almost 14,000 white patients would need to be tested for **57:01* and excluded from receiving the drug in order to prevent one case of DILI; in non-white or mixed populations, this number could be higher [73]. Given the low positive predictive value and the high number needed to test to prevent one case, pre-treatment screening implementation in the clinic is likely not feasible at this time. In their discussion of flucloxacillin *HLA-B*57:01* screening, Phillips *et al.* suggest that a more practical approach is to carefully monitor patients receiving flucloxacillin, and to consider their *HLA-B*57:01* genotype only if there is biochemical evidence for hepatitis, at which point the drug can be stopped [73]. It is uncertain how the presence of the **57:01* allele leads to an increased risk for flucloxacillin-induced DILI. However, it does not appear to be through the same mechanism as **57:01* and abacavir hypersensitivity: Wuillemine *et al.* found that in the presence of the *HLA-B*57:01* molecule, flucloxacillin stimulated T cells (including CD8⁺ T cells) according to the p-i concept [74]. In a later study, Wuillemine *et al.* also showed that DILI might be caused by the infiltration of cytotoxic CD8⁺ and CD3⁺ T cells into the liver [75]. Consideration of the results from both Wuillemine *et al.* studies provides a possible explanation for the connection between **57:01* and DILI.

HLA-B*58:01

Allopurinol—The *HLA-B*58:01* allele is strongly associated with allopurinol-induced SCARs, which include hypersensitivity syndrome (HSS) and SJS/TEN [76]. Allopurinol is mainly used for conditions associated with hyperuricemia, such as gout and tumor lysis syndrome [77]. The drug works by inhibiting the enzyme xanthine oxidase, which is responsible for the conversion of hypoxanthine and xanthine into uric acid. In this manner, the drug lowers the amount of uric acid created in the body [76, 78]. Most side effects from allopurinol are mild, with the most common complaint being gastrointestinal upset [76, 78]. However, allopurinol has also been associated with severe adverse reactions. SJS and TEN (or SJS/TEN when referencing both) are two forms of the same condition. Both involve severe mucocutaneous blistering and epidermal detachment, and usually present one to three weeks after treatment begins. SJS and TEN are distinguished by the amount of skin detachment: SJS is classified as 1-10% detachment of body surface area (BSA), SJS and TEN overlap as 10 – 30% of BSA, and TEN as greater than 30% of BSA. Though the occurrence of these symptoms is rare (only two patients per million per year), SJS and TEN can be permanently disabling or even fatal. The mortality rate correlates with the level of skin detachment, ranging from a 1 – 5% mortality rate for SJS, to a 25 – 35% mortality rate for TEN [79, 80]. In contrast to SJS/TEN, HSS (also known as drug-induced hypersensitivity syndrome (DIHS) or drug reaction with eosinophilia and systemic symptoms (DRESS)) typically has organ involvement, such as hepatitis or nephritis, in addition to fever and a severe rash [81-83]. The risk of developing SCARs during allopurinol

treatment is 0.1 – 0.4% [76]. In some association studies with allopurinol-induced SCARs, only the relationship with SJS/TEN is discussed, and HSS is not used as an associated phenotype.

The first association between *HLA-B*58:01* and SCARs came from a 2005 Taiwanese study on Han Chinese patients, which found that 100% of the 51 patients that developed allopurinol-induced SCARs had the *HLA-B*58:01* allele, while only 15% of the 135 allopurinol-tolerant patients carried the allele. This gave an odds ratio of 580 for development of SCARs with this particular allele [81]. Follow-up studies in Thai, Korean, Japanese, Han Chinese and European populations also found significant results [84-92]. However, differences exist between these ethnicities when considering the magnitude of risk for developing SCARs. While Han Chinese and Thai patients show exceptionally high odds ratios for developing SCARs, European and Japanese **58:01* carriers show comparatively much lower risks for SCAR development (Table 3). This disparity in odds ratios is likely due to variations in **58:01* frequencies between ethnicities, rather than a differing effect of the **58:01* allele depending on ethnicity. While the Han Chinese and Thais tend to have **58:01* allele frequencies of around 8%, Europeans and Japanese have allele frequencies of approximately 1.4% and 0.5%, respectively [6, 88, 90, 91]. The **58:01* allele may also be associated with a more mild cutaneous adverse drug reaction (cADR), maculopapular eruption (MPE), which presents as a rash consisting of macules and papules. Cao *et al.* found that 100% of their Han Chinese patients who developed a MPE while receiving allopurinol carried the **58:01* allele [84]. In contrast, Lee *et al.* found that none of their 12 patients who presented with MPE carried the **58:01* allele, while 6 out of 11 of their patients who developed SCARs did. However, this may be due to the large presence of Caucasians in their study, a population with a low **58:01* frequency. Eleven of the patients with MPE were Caucasian, as were the 5 patients who developed SCARs but did not carry **58:01* [93]. Table 3 provides an overview of allopurinol and **58:01* pharmacogenetic studies, and indicates whether a study has analyzed SCARs, SJS/TEN, HSS or MPE.

Due to the strong associations seen between **58:01* and allopurinol, the CPIC recommends genotyping prior to treatment with allopurinol, and suggests that the drug should be contraindicated in patients with one or more **58:01* alleles [76]. The American College of Rheumatology also recommends that **58:01* screening be considered when assessing the risks of the drug, especially in populations with high frequencies of the allele, such as the Han Chinese or Thais [94]. Unlike abacavir, no clinical trials have been published that test whether genotyping for the presence of *HLA-B*58:01* can reduce the number of SCAR or SJS/TEN cases in patients treated with allopurinol. Based on data from Han Chinese and Thai populations, the negative predictive value of this allele for SJS/TEN development is 100%, but the positive predictive value is only about 1.5% [76]. This indicates that most patients who carry the allele will not develop SJS/TEN. Discovery of new genetic, or non-genetic, factors that lead to SJS/TEN or SCAR development may help increase the positive predictive value. Studies on the mechanism of SCAR development in *HLA-B*58:01* carriers have been limited. A recent study suggested that it is a metabolite of allopurinol, oxypurinol, which causes the hypersensitivity reaction in individuals with the *HLA-B*58:01* allele:

oxypurinol was found to bind to the F pocket of HLA-B*58:01 through the p-i mechanism with a higher affinity compared to allopurinol [95].

HLA-B*15:02

Carbamazepine—*HLA-B*15:02* is strongly associated with SJS/TEN in patients taking carbamazepine, an anticonvulsant and mood-stabilizing drug. Along with epilepsy and bipolar disorder, carbamazepine (CBZ) is also used to treat a variety of other conditions, such as schizophrenia, trigeminal neuralgia and carpal tunnel syndrome [96]. As with *58:01, the allele frequency of *15:02 varies worldwide. Han Chinese have an average allele frequency of almost 6%, but this value can range anywhere from 1.9% to 12.4% depending on the population [6]. Additionally, other Chinese populations, such as the Bulang, can have an allele frequency of close to 36% [97]. Thai and Malaysian populations also have high *15:02 allele frequencies, with average allele frequencies of close to 8%. In contrast, Koreans show a frequency of 0.3%, Japanese a frequency of 0.1%, and Caucasians a frequency of only 0.06% [6]. These percentages correlate with the number and strength of studies finding significant results linking *15:02 with the development of SJS/TEN: studies in Caucasian [98-100] and Japanese [89] patients have been limited and have shown exclusively non-significant results. One study in Koreans found a significant association when comparing allele frequencies for SJS/TEN patients against population controls, but no significant association when comparing against carbamazepine-tolerant controls [101]. In contrast, studies in Han Chinese are numerous and show very high odds ratios for CBZ-induced SJS/TEN [100, 102-107]. Studies in Indian [108], Thai [109-111], Malaysian [112, 113] and Singaporean [114, 115] populations have also seen significant associations. These pharmacogenetic studies are summarized in Table 4. Additionally, three meta-analyses (not included in Table 4) that combined studies with Chinese, Korean, Malaysian and Thai patients, all found odds ratios of approximately 80 for the development of CBZ-induced SJS/TEN in patients carrying the *15:02 allele [116-118].

Due to the low frequency in Korean, Japanese and Caucasian populations, screening for exclusively *15:02 may not be sufficient from a global perspective. Other alleles have shown significant relationships with SJS/TEN within these ethnicities, such as *HLA-B*07:02* [98] and *HLA-A*31:01* [100, 119-121]. Several studies in Japanese, Korean and Han Chinese patients suggest that carriers of the *HLA-B*15:11* alleles [101, 105, 122] have an increased risk of developing SCARs. The average allele frequencies for *15:11 in Japanese and Korean populations are higher than for *15:02, with values of 0.4 - 0.8% for the Japanese, and 1.6% for Koreans [6]. Both *15:02 and *15:11 are part of the same HLA-B75 serotype [101, 122], and the two alleles share a 98.6% amino acid sequence homology [105]. Therefore, they may share similar structures that lead to the triggering of an immune reaction when carbamazepine is administered [105]. Studies on *07:02, *31:01 and *15:11 are limited compared to those on *15:02, and research into alleles beyond *15:02 may help improve predictive genetic testing for SJS/TEN.

Unlike other *HLA-B* alleles, the associations between *HLA-B*15:02* and carbamazepine are phenotype specific. Many of the studies mentioned above ([98-100, 104, 106, 110, 113, 114, 116, 123, 124]) also looked for associations with HSS, as well as MPE. However, none of

the studies found any associations between *15:02 and carbamazepine-induced HSS or MPE, indicating that the allele may be particular to the development of SJS or TEN. One study has assessed the link between *15:11 and carbamazepine-induced HSS, and found no significant association [101]. In contrast, *HLA-A*31:01* has shown strong associations with the development of carbamazepine-induced HSS or MPE in European [99, 100, 120], Han Chinese [100, 123], Japanese [121] and Korean [101] populations, as well as in a meta-analysis which included patients of all four aforementioned ethnicities [116].

A 2011 study assessed the value of genotyping prior to carbamazepine treatment, with close to 4500 Taiwanese subjects of Han Chinese descent participating. The 367 patients who were found to be positive for *15:02 were told not to take the medication, while the remaining 4120 took the drug as normal. Due to ethical considerations, historical incidences of SJS/TEN were used as a control. While no cases of SJS/TEN occurred in the study, historical data estimations found that 10 cases of SJS/TEN would have likely appeared in the study cohort, a significant difference [125]. While those of Caucasian ethnicity do tend to have lower frequencies of the *15:02 allele, genotyping prior to treatment is still valuable for these individuals, as they may be unaware of Asian ancestry, or fail to alert their doctor to their heritage. At this time, the US Food and Drug Administration (FDA) recommends genotyping for *15:02 prior to treatment with carbamazepine in all Asian populations, though does not make recommendations for patients of other ethnicities [126]. The negative predictive value of this allele for patients in Taiwan is suggested to be 100%, and the positive predictive value 7.7% [126]. This low positive predictive value implies that additional genetic or non-genetic factors likely play a role in the development of SJS/TEN in patients taking carbamazepine. Despite the low positive predictive value, it may be advisable to avoid the drug in *15:02-positive patients, given that there are effective alternatives to carbamazepine [119, 126]. Indeed, both CPIC and the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) recommend that a different agent be used if a patient is found to be a carrier of the *15:02 allele, due to a strong increased risk for SJS/TEN [33, 119].

The mechanism of CBZ-induced SJS/TEN is still unclear. In a recent study, Wei *et al.* found that peptide-loaded HLA-B*15:02 presented carbamazepine to cytotoxic T lymphocytes without any prior processing or drug metabolism. Only HLA-B*15:02 could bind CBZ, as opposed to HLA-B*15:01, *15:03, *40:01 or *51:01. Endogenous peptides already loaded onto the molecule were found to be required before CBZ could be presented [127]. The authors suggested that the binding of CBZ to HLA-B*15:02 activates and induces clonal expansion of cytotoxic (CD8+) T lymphocytes, eliciting a severe immune reaction that leads to SJS or TEN [127]. The skin reaction seen in cases of SJS or TEN are thought to be due to CD8+ T lymphocytes, which are found in abundance in skin blister cells of people with SJS/TEN, and are believed to release cytotoxic proteins that induce keratinocyte apoptosis [127-129]. One of the studies that looked at the mechanism of abacavir-induced HSR also found that CBZ binds to HLAB*15:02, but no mention was made regarding whether loaded endogenous peptides are necessary. However, the authors noted that there was a repertoire shift in the peptides bound to HLA-B*15:02 in the presence of CBZ, albeit at a smaller magnitude than that of peptides bound to *57:01 in the presence of abacavir. This change

could lead to an immune reaction by the same mechanism suggested for an abacavir-induced HSR [67]. Further studies in this area should help elucidate the precise manner by which the *15:02 allele affects the development of SJS/TEN in patients taking carbamazepine.

Phenytoin and other antiepileptics—*15:02 is also associated with SJS/TEN in people taking phenytoin, another antiepileptic; pharmacogenetic results are presented in Table 5. Studies linking *15:02 with SJS/TEN include four in Han Chinese patients [130-133] and one in Thai patients limited to SJS cases only [110]. Additionally, a meta-analysis of four studies found a significant association between *15:02 and phenytoin-induced SJS/TEN [118]. Though these studies have shown statistically strong results, they have been limited in number and population size. One study in Thai children found no link between *15:02 and phenytoin-induced SCARs [134]. Variations within the *CYP2C9* gene have also shown associations with phenytoin-related adverse reactions. Phenytoin is primarily metabolized to its inactive form by CYP2C9, and alleles that result in decreased enzymatic activity, specifically *CYP2C9**2 and *3, have been linked with increased phenytoin concentrations [135-138] and an increased risk for neurological toxicities [139, 140] and cutaneous adverse drug reactions [133, 141]. Consideration of both *HLA-B**15:02 and *CYP2C9**2 and *3 may be important in any future clinical pre-treatment screening programs.

Currently, the FDA recommends that physicians consider the risks associated with SJS/TEN in patients taking phenytoin who have Asian ancestry and carry the *15:02 allele, particularly in light of the evidence linking *15:02 with CBZ-induced SJS/TEN [142]. Phenytoin, carbamazepine, oxcarbazepine, phenobarbital and lamotrigine are all known as aromatic antiepileptic drugs (AEDs) due to the presence of an aromatic ring in their structure – symptoms of hypersensitivity were found to occur twice as often in patients given aromatic AEDs as opposed to non-aromatic AEDs (e.g. levetiracetam or topiramate) [143], suggesting that the presence of the ring may be involved in the higher risk for adverse reactions [144]. A recent study looking at children taking carbamazepine, oxcarbazepine or phenobarbital found that those who developed SJS had a higher frequency of the *15:02 allele as compared to tolerant controls or healthy population controls [145]. Wei *et al.*, in their study on the mechanism by which *15:02 is associated with CBZ-induced SJS/TEN, noted that oxcarbazepine, which has a tricyclic ring structure similar to CBZ, was also capable of binding with *HLA-B**15:02, though not as strongly as CBZ [127]. However, studies linking *HLA-B**15:02 with oxcarbazepine-induced SJS or MPE have shown mixed results [131, 146-148]. Though no individual studies have found significant associations between *15:02 and lamotrigine-induced adverse reactions [130, 131, 149, 150], a meta-analysis of four studies did find a significantly increased risk for SJS/TEN for patients carrying *15:02 who receive lamotrigine [118].

Conclusions

The *HLA-B* gene has shown associations with a wide range of diseases and adverse drug reactions. Despite this, very little is understood about the mechanisms by which variations in an immune system gene can affect the propensity for certain pharmacological reactions or particular illnesses. However, some progress has been made in understanding the

mechanisms behind abacavir HSRs and carbamazepine-induced SJS/TEN, particularly in the last couple years. Studies on abacavir HSRs have paved the way for pharmacogenetic implementation within the clinic: *HLA-B*57:01* genotyping prior to abacavir treatment is one of the key examples of pharmacogenetics being used in routine medical practice. Given that *HLA-B*58:01* and **15:02* have also shown strong pharmacogenetic associations, these alleles may also be good candidates for clinical integration. *HLA-B* has been shown to be an influential gene across many areas of medicine, and future studies should improve our understanding of its role in both disease and pharmacology.

Acknowledgements

This work is supported by the NIH/NIGMS (R24 GM61374) and NIH grant U01 GM061390. The authors thank Ellen McDonagh for critical reading of this manuscript.

References

1. Horton R, et al. Gene map of the extended human MHC. *Nat Rev Genet.* 2004; 5(12):889–99. [PubMed: 15573121]
2. Neefjes J, et al. Towards a systems understanding of MHC class I and MHC class II antigen presentation. *Nat Rev Immunol.* 2011; 11(12):823–36. [PubMed: 22076556]
3. Xie T, et al. Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse. *Genome Res.* 2003; 13(12):2621–36. [PubMed: 14656967]
4. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. *Nat Rev Immunol.* 2008; 8(8):607–18. [PubMed: 18641646]
5. Janeway, CAJT.; P.; Walport, M.; Shlomchik, MJ. *Immunobiology: The Immune System in Health and Disease.* Garland Science; New York: 2001.
6. Gonzalez-Galarza FF, et al. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. *Nucleic Acids Res.* 2011; 39(Database issue):D913–9. [PubMed: 21062830]
7. Robinson J, et al. The IMGT/HLA database. *Nucleic Acids Res.* 2011; 39(Database issue):D1171–6. [PubMed: 21071412]
8. Martin MA, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. *Clin Pharmacol Ther.* 2012; 91(4):734–8. [PubMed: 22378157]
9. Hill AV, et al. Common west African HLA antigens are associated with protection from severe malaria. *Nature.* 1991; 352(6336):595–600. [PubMed: 1865923]
10. Hill AV, et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. *Nature.* 1992; 360(6403):434–9. [PubMed: 1280333]
11. Mizuki N, et al. Localization of the pathogenic gene of Behcet's disease by microsatellite analysis of three different populations. *Invest Ophthalmol Vis Sci.* 2000; 41(12):3702–8. [PubMed: 11053265]
12. Remmers EF, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. *Nat Genet.* 2010; 42(8):698–702. [PubMed: 20622878]
13. Li Y, et al. Association between HLA-B*46 allele and Graves disease in Asian populations: a meta-analysis. *Int J Med Sci.* 2013; 10(2):164–70. [PubMed: 23329888]
14. Altfeld M, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. *AIDS.* 2003; 17(18):2581–91. [PubMed: 14685052]
15. Klooverpris HN, et al. HLA-B*57 Micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection pressure, and HIV immune control. *J Virol.* 2012; 86(2):919–29. [PubMed: 22090105]
16. Kosmrlj A, et al. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. *Nature.* 2010; 465(7296):350–4. [PubMed: 20445539]

17. McLaren PJ, et al. Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. *Hum Mol Genet.* 2012; 21(19):4334–47. [PubMed: 22718199]
18. Migueles SA, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. *Proc Natl Acad Sci U S A.* 2000; 97(6): 2709–14. [PubMed: 10694578]
19. Pelak K, et al. Host determinants of HIV-1 control in African Americans. *J Infect Dis.* 2010; 201(8):1141–9. [PubMed: 20205591]
20. Poropatich K, Sullivan DJ Jr. Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. *J Gen Virol.* 2011; 92(Pt 2):247–68. [PubMed: 21106806]
21. Prentice HA, et al. HLA-B*57 versus HLA-B*81 in HIV-1 infection: slow and steady wins the race? *J Virol.* 2013; 87(7):4043–51. [PubMed: 23365442]
22. Braun J, Sieper J. Ankylosing spondylitis. *Lancet.* 2007; 369(9570):1379–90. [PubMed: 17448825]
23. Reveille JD. Major histocompatibility genes and ankylosing spondylitis. *Best Pract Res Clin Rheumatol.* 2006; 20(3):601–9. [PubMed: 16777585]
24. McHugh K, Bowness P. The link between HLA-B27 and SpA--new ideas on an old problem. *Rheumatology (Oxford).* 2012; 51(9):1529–39. [PubMed: 22513152]
25. Chen L, et al. Critical role of endoplasmic reticulum aminopeptidase 1 in determining the length and sequence of peptides bound and presented by HLAB27. *Arthritis Rheumatol.* 2014; 66(2): 284–94. [PubMed: 24504800]
26. Cortes A, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nat Genet.* 2013; 45(7):730–8. [PubMed: 23749187]
27. Evans DM, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nat Genet.* 2011; 43(8): 761–7. [PubMed: 21743469]
28. Smith JA, Colbert RA. Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. *Arthritis Rheumatol.* 2014; 66(2):231–41. [PubMed: 24504793]
29. Hammond E, et al. External quality assessment of HLA-B*5701 reporting: an international multicentre survey. *Antivir Ther.* 2007; 12(7):1027–32. [PubMed: 18018760]
30. Stevens R, et al. Comprehensive evaluation of two HLA-B17 monoclonal antibodies for flow cytometry-based HLA-B57/B58 screening prior to abacavir prescription. *Int J Immunogenet.* 2013; 40(4):311–5. [PubMed: 23280011]
31. Kostenko L, et al. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. *Tissue Antigens.* 2011; 78(1):11–20. [PubMed: 21501118]
32. Martin AM, et al. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. *Pharmacogenet Genomics.* 2006; 16(5):353–7. [PubMed: 16609367]
33. Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. *Clin Pharmacol Ther.* 2013; 94(3):324–8. [PubMed: 23695185]
34. Colombo S, et al. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. *J Infect Dis.* 2008; 198(6):864–7. [PubMed: 18684101]
35. Rodriguez-Novoa S, et al. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. *J Antimicrob Chemother.* 2010; 65(8):1567–9. [PubMed: 20534626]
36. Sanchez-Giron F, et al. Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos. *Pharmacogenomics.* 2011; 12(6):809–14. [PubMed: 21510768]
37. de Bakker PI, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. *Nat Genet.* 2006; 38(10):1166–72. [PubMed: 16998491]

38. Badulli C, et al. Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B*57:01 typing for eligibility to abacavir treatment in the Italian population. *Pharmacogenomics*. 2012; 13(3):247–9. [PubMed: 22304574]
39. Melis R, et al. Copy number variation and incomplete linkage disequilibrium interfere with the HCP5 genotyping assay for abacavir hypersensitivity. *Genet Test Mol Biomarkers*. 2012; 16(9): 1111–4. [PubMed: 22913531]
40. Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. *Pharmacogenomics*. 2010; 11(7):973–87. [PubMed: 20602616]
41. Rive CM, Bourke J, Phillips EJ. Testing for drug hypersensitivity syndromes. *Clin Biochem Rev*. 2013; 34(1):15–38. [PubMed: 23592889]
42. White, KDG.; S.; Phillips, EJ. HLA and the Pharmacogenomics of Drug Hypersensitivity. In: Padmanabhan, S., editor. *Handbook of Pharmacogenomics and Stratified Medicine*. Elsevier; London: 2014.
43. De Santis D, et al. 16(th) IHIW : review of HLA typing by NGS. *Int J Immunogenet*. 2013; 40(1): 72–6. [PubMed: 23302098]
44. Erlich H. HLA DNA typing: past, present, and future. *Tissue Antigens*. 2012; 80(1):1–11. [PubMed: 22651253]
45. Hosomichi K, et al. Phase-defined complete sequencing of the HLA genes by next-generation sequencing. *BMC Genomics*. 2013; 14:355. [PubMed: 23714642]
46. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. *Clin Pharmacokinet*. 2008; 47(6):351–71. [PubMed: 18479171]
47. Escaut L, et al. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. *AIDS*. 1999; 13(11):1419–20. [PubMed: 10449301]
48. Mallal S, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *Lancet*. 2002; 359(9308):727–32. [PubMed: 11888582]
49. Hetherington S, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. *Lancet*. 2002; 359(9312):1121–2. [PubMed: 11943262]
50. Hughes DA, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. *Pharmacogenetics*. 2004; 14(6):335–42. [PubMed: 15247625]
51. Rauch A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. *Clin Infect Dis*. 2006; 43(1):99–102. [PubMed: 16758424]
52. Waters LJ, et al. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. *AIDS*. 2007; 21(18):2533–4. [PubMed: 18025891]
53. Zucman D, et al. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. *J Acquir Immune Defic Syndr*. 2007; 45(1):1–3. [PubMed: 17356469]
54. Hughes AR, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. *Pharmacogenomics*. 2004; 5(2):203–11. [PubMed: 15016610]
55. Saag M, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. *Clin Infect Dis*. 2008; 46(7):1111–8. [PubMed: 18444831]
56. Munderi P, et al. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. *Trop Med Int Health*. 2011; 16(2):200–4. [PubMed: 21091860]
57. Mallal S, et al. HLA-B*5701 screening for hypersensitivity to abacavir. *N Engl J Med*. 2008; 358(6):568–79. [PubMed: 18256392]
58. Phillips EJ, et al. Drug hypersensitivity: pharmacogenetics and clinical syndromes. *J Allergy Clin Immunol*. 2011; 127(3 Suppl):S60–6. [PubMed: 21354501]
59. Pavlos R, et al. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. *J Allergy Clin Immunol Pract*. 2014; 2(1):21–33. [PubMed: 24565765]

60. Barbarino JM, et al. PharmGKB summary: abacavir pathway. *Pharmacogenet Genomics*. 2014; 24(5):276–82. [PubMed: 24625462]
61. Martin AM, et al. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. *AIDS*. 2007; 21(10):1233–44. [PubMed: 17545699]
62. Martin AM, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. *Proc Natl Acad Sci U S A*. 2004; 101(12):4180–5. [PubMed: 15024131]
63. Administration, U.S.F.a.D. ZIAGEN (abacavir sulfate) drug label. 2013
64. Agency, E.M. ZIAGEN: EPAR - Product Information. 2013
65. Swen JJ, et al. Pharmacogenetics: from bench to byte--an update of guidelines. *Clin Pharmacol Ther*. 2011; 89(5):662–73. [PubMed: 21412232]
66. Pichler WJ, et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. *Allergol Int*. 2006; 55(1):17–25. [PubMed: 17075282]
67. Illing PT, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. *Nature*. 2012; 486(7404):554–8. [PubMed: 22722860]
68. Ostrov DA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. *Proc Natl Acad Sci U S A*. 2012; 109(25):9959–64. [PubMed: 22645359]
69. Norcross MA, et al. Abacavir induces loading of novel self-peptides into HLAB*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. *AIDS*. 2012; 26(11):F21–9. [PubMed: 22617051]
70. Phillips EJ, et al. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. *AIDS*. 2002; 16(16):2223–5. [PubMed: 12409746]
71. Daly AK, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nat Genet*. 2009; 41(7):816–9. [PubMed: 19483685]
72. Vera JH, et al. The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype. *AIDS*. 2013; 27(3):484–5. [PubMed: 23032409]
73. Phillips EJ, Mallal SA. HLA-B*5701 and flucloxacillin associated drug-induced liver disease. *AIDS*. 2013; 27(3):491–2. [PubMed: 23291545]
74. WUILLEMIN N, et al. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. *J Immunol*. 2013; 190(10):4956–64. [PubMed: 23596311]
75. WUILLEMIN N, et al. T cells infiltrate the liver and kill hepatocytes in HLA-B(*)57:01-associated floxacillin-induced liver injury. *Am J Pathol*. 2014; 184(6):1677–82. [PubMed: 24731753]
76. Hershfield MS, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. *Clin Pharmacol Ther*. 2013; 93(2):153–8. [PubMed: 23232549]
77. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. *Pharmacol Rev*. 2006; 58(1):87–114. [PubMed: 16507884]
78. Lam MP, Yeung CK, Cheung BM. Pharmacogenetics of allopurinol--making an old drug safer. *J Clin Pharmacol*. 2013; 53(7):675–9. [PubMed: 23381951]
79. Fernando SL, Broadfoot AJ. Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening. *CMAJ*. 2010; 182(5):476–80. [PubMed: 19933789]
80. Lee MT, et al. Pharmacogenetics of toxic epidermal necrolysis. *Expert Opin Pharmacother*. 2010; 11(13):2153–62. [PubMed: 20536296]
81. Hung SI, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. *Proc Natl Acad Sci U S A*. 2005; 102(11):4134–9. [PubMed: 15743917]
82. Rademaker, M.a.M.; T.. Prescriber Update Articles. *Drug Hypersensitivity Syndrome*. Nov 7th. 2003 2014.
83. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. *N Engl J Med*. 1994; 331(19): 1272–85. [PubMed: 7794310]
84. Cao ZH, et al. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. *Pharmacogenomics*. 2012; 13(10):1193–201. [PubMed: 22909208]

85. Chiu ML, et al. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. *Br J Dermatol*. 2012; 167(1):44–9. [PubMed: 22348415]
86. Goncalo M, et al. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. *Br J Dermatol*. 2013; 169(3):660–5. [PubMed: 23600531]
87. Jung JW, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. *Nephrol Dial Transplant*. 2011; 26(11):3567–72. [PubMed: 21393610]
88. Kang HR, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. *Pharmacogenet Genomics*. 2011; 21(5):303–7. [PubMed: 21301380]
89. Kaniwa N, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. *Pharmacogenomics*. 2008; 9(11): 1617–22. [PubMed: 19018717]
90. Lonjou C, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. *Pharmacogenet Genomics*. 2008; 18(2):99–107. [PubMed: 18192896]
91. Tassaneeyakul W, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. *Pharmacogenet Genomics*. 2009; 19(9):704–9. [PubMed: 19696695]
92. Tohkin M, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. *Pharmacogenomics J*. 2013; 13(1):60–9. [PubMed: 21912425]
93. Lee MH, et al. Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? *Intern Med J*. 2012; 42(4):411–6. [PubMed: 21790926]
94. Khanna D, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res (Hoboken)*. 2012; 64(10):1431–46. [PubMed: 23024028]
95. Yun J, et al. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. *J Immunol*. 2014; 192(7):2984–93. [PubMed: 24591375]
96. Chung WH, Hung SI, Chen YT. Genetic predisposition of life-threatening antiepileptic-induced skin reactions. *Expert Opin Drug Saf*. 2010; 9(1):15–21. [PubMed: 20001755]
97. Shi L, et al. Genetic link among Hani, Bulang and other Southeast Asian populations: evidence from HLA -A, -B, -C, -DRB1 genes and haplotypes distribution. *Int J Immunogenet*. 2010; 37(6): 467–75. [PubMed: 20637045]
98. Alfrevic A, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. *Pharmacogenomics*. 2006; 7(6):813–8. [PubMed: 16981842]
99. Amstutz U, et al. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. *Clin Pharmacol Ther*. 2013; (1):142–9. [PubMed: 23588310]
100. Genin E, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. *Pharmacogenomics J*. 2014; 14(3): 281–8. [PubMed: 24322785]
101. Kim SH, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. *Epilepsy Res*. 2011; 97(1-2):190–7. [PubMed: 21917426]
102. Chung WH, et al. Medical genetics: a marker for Stevens-Johnson syndrome. *Nature*. 2004; 428(6982):486. [PubMed: 15057820]
103. He XJ, et al. Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China. *Pharmacol Rep*. 2013; 65(5):1256–62. [PubMed: 24399721]
104. Hsiao YH, et al. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. *J Dermatol Sci*. 2014; 73(2):101–9. [PubMed: 24268988]
105. Shi YW, et al. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502? *Basic Clin Pharmacol Toxicol*. 2012; 111(1):58–64. [PubMed: 22348435]

106. Wang Q, et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. *Seizure*. 2011; 20(6): 446–8. [PubMed: 21397523]
107. Zhang Y, et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. *Eur J Clin Pharmacol*. 2011; 67(9):885–7. [PubMed: 21424386]
108. Mehta TY, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. *Indian J Dermatol Venereol Leprol*. 2009; 75(6):579–82. [PubMed: 19915237]
109. Kulkantrakorn K, et al. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. *Pain Pract*. 2012; 12(3):202–8. [PubMed: 21676164]
110. Lochareonkul C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. *Epilepsia*. 2008; 49(12):2087–91. [PubMed: 18637831]
111. Tassaneeyakul W, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. *Epilepsia*. 2010; 51(5):926–30. [PubMed: 20345939]
112. Chang CC, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. *Int J Dermatol*. 2011; 50(2):221–4. [PubMed: 21244392]
113. Then SM, et al. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. *Asian Pac J Allergy Immunol*. 2011; 29(3):290–3. [PubMed: 22053601]
114. Chong KW, et al. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. *Arch Dis Child*. 2014; 99(6):581–4. [PubMed: 24225276]
115. Toh DS, et al. Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study. *Pharmacogenomics J*. 2014; 14(4):316–21. [PubMed: 24394201]
116. Grover S, Kukreti R. HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. *Pharmacogenet Genomics*. 2014; 24(2):94–112. [PubMed: 24336023]
117. Tangamornsuksan W, et al. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. *JAMA Dermatol*. 2013; 149(9):1025–32. [PubMed: 23884208]
118. Bloch KM, et al. Pharmacogenetics of antiepileptic drug-induced hypersensitivity. *Pharmacogenomics*. 2014; 15(6):857–68. [PubMed: 24897291]
119. Amstutz U, et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. *Epilepsia*. 2014; 55(4):496–506. [PubMed: 24597466]
120. McCormack M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. *N Engl J Med*. 2011; 364(12):1134–43. [PubMed: 21428769]
121. Ozeki T, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. *Hum Mol Genet*. 2011; 20(5):1034–41. [PubMed: 21149285]
122. Kaniwa N, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. *Epilepsia*. 2010; 51(12):2461–5. [PubMed: 21204807]
123. Hung SI, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. *Pharmacogenet Genomics*. 2006; 16(4):297–306. [PubMed: 16538176]
124. Wu XT, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. *Epilepsy Behav*. 2010; 19(3):405–8. [PubMed: 20833111]

125. Chen P, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. *N Engl J Med.* 2011; 364(12):1126–33. [PubMed: 21428768]
126. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. *Pharmacogenomics.* 2008; 9(10): 1543–6. [PubMed: 18855540]
127. Wei CY, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. *J Allergy Clin Immunol.* 2012; 129(6):1562–9. e5. [PubMed: 22322005]
128. Chung WH, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. *Nat Med.* 2008; 14(12):1343–50. [PubMed: 19029983]
129. Leyva L, et al. Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response. *J Allergy Clin Immunol.* 2000; 105(1 Pt 1):157–65. [PubMed: 10629466]
130. Cheung YK, et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. *Epilepsia.* 2013; 54(7):1307–14. [PubMed: 23692434]
131. Hung SI, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. *Pharmacogenomics.* 2010; 11(3):349–56. [PubMed: 20235791]
132. Min FL, et al. HLA-B*1502 genotyping in two Chinese patients with phenytoin-induced Stevens-Johnson syndrome. *Epilepsy Behav.* 2011; 20(2):390–1. [PubMed: 21216202]
133. Chung WH, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. *JAMA.* 2014; 312(5):525–34. [PubMed: 25096692]
134. Manuyakorn W, et al. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children. *Pediatr Allergy Immunol.* 2013; 24(3):299–303. [PubMed: 23551241]
135. Odani A, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. *Clin Pharmacol Ther.* 1997; 62(3):287–92. [PubMed: 9333104]
136. Ramasamy K, et al. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients. *Ther Drug Monit.* 2010; 32(6):762–6. [PubMed: 21068649]
137. Soga Y, et al. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. *Life Sci.* 2004; 74(7):827–34. [PubMed: 14659971]
138. Phabphal K, et al. Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients. *Seizure.* 2013; 22(2):103–8. [PubMed: 23159358]
139. Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. *Eur J Clin Pharmacol.* 2010; 66(7):689–96. [PubMed: 20390258]
140. Hennessy S, et al. CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. *J Clin Pharmacol.* 2009; 49(12):1483–7. [PubMed: 19617466]
141. Lee AY, et al. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. *Eur J Clin Pharmacol.* 2004; 60(3):155–9. [PubMed: 15024534]
142. Kuehn BM. FDA: Epilepsy drugs may carry skin risks for Asians. *JAMA.* 2008; 300(24):2845. [PubMed: 19109108]
143. Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. *Pharmacotherapy.* 2007; 27(10):1425–39. [PubMed: 17896897]
144. Handoko KB, et al. Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs: the role of the aromatic ring. *Drug Saf.* 2008; 31(8):695–702. [PubMed: 18636788]
145. Sun D, et al. Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China. *J Huazhong Univ Sci Technolog Med Sci.* 2014; 34(1):146–50. [PubMed: 24496695]

146. He N, et al. Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles. *Seizure*. 2012; 21(8):614–8. [PubMed: 22818943]
147. Hu FY, et al. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population. *Seizure*. 2011; 20(2):160–2. [PubMed: 21169036]
148. Lv YD, et al. The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population. *BMC Neurol*. 2013; 13:75. [PubMed: 23829937]
149. An DM, et al. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population. *Epilepsy Res*. 2010; 92(2-3):226–30. [PubMed: 21071176]
150. Shi YW, et al. Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. *Basic Clin Pharmacol Toxicol*. 2011; 109(1):42–6. [PubMed: 21306565]
151. Yip VL, et al. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. *Clin Pharmacol Ther*. 2012; 92(6):757–65. [PubMed: 23132554]
152. Berka N, et al. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta. *Hum Immunol*. 2012; 73(2):164–7. [PubMed: 22197535]
153. Huang YC, et al. Allopurinol-induced drug rash with eosinophilia and systemic symptoms mimicking acute generalized exanthematous pustulosis. *J Dermatol*. 2012; 39(12):1077–8. [PubMed: 22901319]
154. Lee MH, et al. HLA-B*5801 should be used to screen for risk of Stevens- Johnson syndrome in family members of Han Chinese patients commencing allopurinol therapy. *J Rheumatol*. 2013; 40(1):96–7. [PubMed: 23280169]
155. Dainichi T, et al. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? *Dermatology*. 2007; 215(1):86–8. [PubMed: 17587850]
156. Kemen C, et al. Human leukocyte antigen-related risk factors for toxic epidermal necrosis. *Pediatr Infect Dis J*. 2009; 28(6):552. [PubMed: 19483528]
157. Lonjou C, et al. A marker for Stevens-Johnson syndrome ...: ethnicity matters. *Pharmacogenomics J*. 2006; 6(4):265–8. [PubMed: 16415921]

Table 1
List of *HLA-B* alleles and their associated drug phenotypes

The phenotypes listed for each drug are more likely to occur in patients who carry the associated allele. For example, carriers of *57:01 who are given abacavir have an increased chance of a hypersensitivity reaction as compared to non-carriers. When available, positive and negative predictive values are also shown. An interactive version of this table is available online at <http://www.pharmgkb.org/gene/PA35056>.

HLA-B risk allele	Drug	Phenotype	Ref	PPV	NPV	Ref
*57:01	Abacavir	Hypersensitivity reaction	See Table 2	55%	100%	[41, 57]
	Flucloxacillin	Drug-induced liver injury	[57, 71]			
*58:01	Allopurinol	SCARs, MPE	See Table 3	1.5%	100%	[91]
*15:02	Carbamazepine	SJS/TEN	See Table 4	1.8%	100%	[151]
	Phenytoin	SJS/TEN	See Table 5	33% ¹	100% ¹	[111]

PPV, positive predictive value; NPV, negative predictive value; SCARs, severe cutaneous adverse reactions; MPE, maculopapular eruption; SJS/TEN, Stevens-Johnson Syndrome/toxic epidermal necrolysis

¹ For phenytoin-induced SJS only.

Table 2
Summary of abacavir and *HLA-B*57:01* pharmacogenetic studies

p-values and odds ratios (ORs) listed pertain to the risk for an abacavir hypersensitivity reaction (HSR) in patients carrying the **57:01* allele as compared to non-carriers. p-values and ORs were calculated by comparing the frequency of **57:01* in patients who developed an HSR compared to the frequency in abacavir-tolerant controls. Prevalence of **57:01* is listed for patients who developed an HSR (case) and in those who were abacavir-tolerant (control). An interactive version of this table is available online at [http:// www.pharmgkb.org/haplotype/PA165956565](http://www.pharmgkb.org/haplotype/PA165956565), and is updated as new results come to our attention.

	Population	<i>*57:01</i> prevalence	p-value	OR (95% CI)	Ref
American	White (74%)				[49]
	Black (14%)	Case: 37/84 (44%)			
	Hispanic (11%)	Control: 1/113 (0.9%)			
	Other (2%) ¹				
	White (66%)	Case: 91/189 ² (48%)	8.4 × 10 ⁻²³	21.4 (9.5 – 48.1)	[50]
		Control: 7/171 (4%)			
	Hispanic (19%)	Case: 11/51 ² (22%)	2.1 × 10 ⁻⁴	30.4 (1.7 – 531)	
		Control: 0/53 (0%)			
	Black (15%)	Case: 3/37 ² (8%)	0.27	3.5 (0.4 – 35.5)	
		Control: 1/41 (2%)			
Australian	White (54%)	Case: 42/42 ³ (100%)			[55]
		Control: 8/202 (4%)		1945 (110 – 34352)	
	Black (46%)	Case: 5/5 ³ (100%)			
		Control: 2/206 (1%)		900 (38 – 21045)	
British	Caucasian (88%)				[48]
	African (3.5%)	Case: 14/18 (78%)			
	Indigenous (5.5%)	Control: 4/167 (2%)	< 0.0001	117 (29 - 481)	
	Asian (3%)				
Canadian	Caucasian (94%)	Case: 6/13 (46%)			[50]
	Other (6%) ¹	Control: 5/51 (10%)	0.006	7.9 (1.5 – 41.4)	
Ugandan	White (66%)				[152]
	Black (16%)	Case: 18/18 (100%)			
	Aboriginal (6%)	Control: 2/470 (0.4%)	<0.0001	6934 (321 – 149035)	
	Other (12%) ⁴				
Ugandan		Case: 0/6 (0%) ⁵			[56]
		Control: 0/241 (0%)			

¹ Unspecified remaining races

² Data using a 'standard' case definition: cases of hypersensitivity were either "definite/probable" or "possible". Results differed but were still significant for White and Hispanic patients (and still non-significant for Black patients) using a "restrictive" case definition - only cases that were "definite/probable". For "restrictive" case definition data, please refer to the paper directly.

³Immunologically confirmed HSRs. For clinically confirmed HSR data, please refer to the paper directly.

⁴Including 4.7% Indo-Asian, 3.1% Hispanic, 2% Metis and 2.2% Oriental or Unknown.

⁵Clinically confirmed HSRs.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3
Summary of allopurinol and *58:01 pharmacogenetic studies

p-values and odds ratios (ORs) listed pertain to the risk for allopurinol-induced adverse reactions in patients carrying the *58:01 allele as compared to non-carriers. p-values and ORs were calculated by comparing the frequency of *58:01 in patients who developed adverse reactions to the frequency of *58:01 in allopurinol-tolerant controls or in healthy population controls. Prevalence of *58:01 is listed for patients who developed adverse reactions (case) and in those who were allopurinol-tolerant (tolerant control) or from a healthy population (population control). An interactive version of this table is available online at <http://www.pharmgkb.org/haplotype/PA165956630>, and is updated as new results come to our attention.

Population	*58:01 prevalence	p-value	Odds ratio (95% CI)	Ref
Australian	Case (SCARs) ¹ : 6/11 (55%)			[93]
	Case (MPE) ² : 0/12 (0%)			
European	Case (SJS/TEN; Caucasians only): 15/27 (55%)			[90]
	Case (SJS/TEN; Mixed ethnicities) ³ : 19/31 (61%)			
	Population control ⁴ : 28/1822 (1.5%)			
	vs Caucasians only	$<1 \times 10^{-6}$	80 (34 – 187)	
	vs Mixed ethnicities	$<1 \times 10^{-8}$	61 (32 – 118)	
	Case (SCARs) ⁵ : 16/25 (64%)			[86]
Han Chinese	Tolerant control ⁶ : 1/23 (4.3%)	5.9×10^{-4}	39.1 (4.5 – 340)	
	Population control ⁶ : 63/3200 (2%)		88.5 (38 – 208)	
	Case (SCARs): 51/51 (100%)			[81]
	Tolerant control: 20/135 (15%)	4.7×10^{-24}	580 (34 – 9781)	
	Population control: 19/93 (20%)	8.1×10^{-18}	393 (23 – 6625)	
	Case (SCARs): 19/19 (100%)			[85]
	Tolerant control: 4/30 (13%)		230 (11.7 – 4520)	
	Case (SCARs): 16/16 (100%)			[84]
	Case (MPE): 22/22 (100%)			
	Case (All cADRs) ⁷ : 38/38 (100%)			
	Tolerant control: 7/63 (11%)			
	vs SCAR cases	7.4×10^{-12}	248 (13.5 – 4585)	
	vs MPE cases	9.2×10^{-14}	339 (18.6 – 6186)	
	vs cADR cases	7.0×10^{-18}	580 (32.1 – 10457)	
	Population control: 80/572 (14%)			
	vs SCAR cases	1.8×10^{-18}	202 (12 – 3398)	
	vs MPE cases	3.7×10^{-24}	275 (16.5 – 4584)	
	vs cADR cases	3.2×10^{-38}	471 (28.7 – 7744)	
	Case (HSS): 1/1 (100%)			[153]
	Case (SJS): 1/1 (100%)			[154]
	Tolerant control: 0/1 (0%)			

Population	*58:01 prevalence	p-value	Odds ratio (95% CI)	Ref
Japanese	Case (SJS/TEN): 4/20 ⁸ (20%)			[89]
	Population control: 6/986 ⁸ (0.6%)	<0.0001	40.8 (10.5 – 159)	
	Case (SJS/TEN): 10/36 ⁸ (28%)			[92]
	Population control: 6/986 ⁸ (0.6%)	5.4×10^{-12}	62.8 (21.2 – 186)	
	Case (SCARs): 3/3 (100%)			[155]
Kenyan	Case (TEN) ⁹ : 1/1			[156]
Korean	Case (SCARs): 24/26 (92%)			[88]
	Tolerant control: 6/57 (11%)	2.5×10^{-11}	97.8 (18.3 – 522)	
	Population control: 59/485 (12%)	2.5×10^{-16}	83.0 (19.0 – 361)	
	Case (SCARs): 9/9 (100%)			[87]
	Tolerant control: 41/432 (9.5%)	<0.001	179 (10.2 – 3152)	
Thai	Population control: 59/485 (12%)	<0.001	136 (7.8 – 2381)	
	Case (SJS/TEN): 27/27 (100%)			[91]
	Tolerant control: 7/54 (13%)	1.6×10^{-13}	348 (19.2 – 6337)	

SCARs, severe cutaneous adverse drug reactions; SJS/TEN, Stevens-Johnson Syndrome/toxic epidermal necrolysis; MPE, maculopapular eruption; cADRs, cutaneous adverse drug reactions; HSS, hypersensitivity syndrome.

¹ 4 of the 6 patients with *58:01 were of Southeast Asian origin, and two were Caucasian. All patients with SCARs but without *58:01 (i.e. the 5 remaining patients) were Caucasian.

² One patient was of Southeast Asian origin, the remaining patients were Caucasian.

³ Includes 27 Caucasian patients, and four non-Caucasian patients of Pakistani, Cuban, Indian and Senegalese background; all four non-Caucasian patients carried the *58:01 allele.

⁴ Controls came from Western Europe but specific ethnic information was not provided; the majority of these controls were assumed to be Caucasian.

⁵ Cases were exclusively Caucasian.

⁶ Ethnicity of the controls was not specified.

⁷ MPE and SCAR.

⁸ Allele frequencies.

⁹ Born in Germany to Kenyan parents

Table 4
Summary of carbamazepine and *15:02 pharmacogenetic studies

p-values and odds ratios (ORs) listed pertain to the risk for carbamazepine-induced Stevens-Johnson Syndrome or toxic epidermal necrolysis (SJS/TEN) in patients carrying the *15:02 allele as compared to non-carriers. p-values and ORs were calculated by comparing the frequency of *15:02 in patients who developed SJS/TEN to the frequency in carbamazepine-tolerant controls or in healthy population controls. Prevalence of *15:02 is listed for patients who developed SJS/TEN (case) and in those who were carbamazepine-tolerant (tolerant control) or from a healthy population (population control). An interactive version of this table is available online at <http://www.pharmgkb.org/haplotype/PA165954769>, and is updated as new results come to our attention.

Population	*15:02 prevalence	p-value	Odds ratio (95% CI)	Ref
British ¹	Case: 0/2 (0%)			[98]
	Tolerant control: 0/43 (0%)			
Canadian ²	Case: 3/9 (33%) ³			[99]
	Tolerant control: 1/87 (1%) ⁴	0.002	38.7 (2.7 – 2240)	
European	Case: 4/12 (33%) ⁵			[157]
	Cases: 0/20 (0%)			[100]
	Tolerant control: 0/43 (0%)	NS		
	Population control: 4/8862 (0.1%)	NS		
Han Chinese	Case: 9/9 (100%)			[106]
	Tolerant control: 11/80 (13.8%)	<0.001	115 (6.3 – 2111)	
	Population control: 11/62 (17.7%)	<0.001	85.1 (4.6 – 1570)	
	Case: 16/17 (94%)			[107]
	Tolerant control: 2/21 (9.5%)	<0.0001	152 (12 – 1835)	
	Population control: 17/185 (9.2%)	<0.0001	158 (19 – 1266)	
	Case: 44/44 (100%)			[102]
	Tolerant control: 3/101 (3%)	3.1×10^{-27}	2504 (126 – 49522)	
	Population control: 8/93 (8.6%)	1.4×10^{-21}	895 (50 – 15869)	
	Case: 59/60 (98.3%)			[123]
	Tolerant control: 6/144 (4.2%)	1.6×10^{-41}	1357 (193 – 8838)	
	Case: 13/18 (72.2%)			[105]
	Tolerant control: 12/93 (12.9%)	<0.001	17.6 (5.3 – 58.1)	
	Population control: 10/93 (10.8%)	<0.001	21.6 (6.4 – 73.3)	
	Case: 24/26 (92.3%)			[130]
	Tolerant control: 16/135 (11.9%)	3.5×10^{-18}	89.3 (19 – 414)	
	Case: 8/8 (100%)			[124]
	Tolerant control: 4/50 (8%)		184 (33.2 – 1021)	
	Population control: 6/71 (8.5%)		173 (36 – 835)	
	Case: 99/112 (88%)			[104]
	Tolerant control: 11/152 (7%)	5.8×10^{-43}	97.6 (42 – 227)	
	Case: 8/35 (22.9%)			[103]

Population	*15:02 prevalence	p-value	Odds ratio (95% CI)	Ref
	Tolerant control: 2/125 (1.6%)	0.000	18.2 (3.7 – 90.7)	[100]
	Case: 41/53 (77.4%)			
	Tolerant control: 4/72 (5.6%)	< 0.001	58.1 (17.6 – 192)	
	Population control: 60/710 (8.5%)	< 0.001	37.0 (18.5 – 74.2)	
Indian	Case (SJS only): 6/8 (75%)			[108]
Japanese	Tolerant control: 0/10 (0%)	0.0014	71.4 (3.0 – 1698)	[89]
	Case: 0/7 (0%)			
Korean	Case: 1/7 (14.3%)			[101]
Malaysian	Tolerant control: 2/50 (4%)	NS	23.3 (0.9 – 634)	[112]
	Population control: 2/485 (0.4%)	0.042	40.3 (3.2 – 506)	
	Case: 12/16 (75%)			
	Population control: 47/300 (15.7%)	7.9×10^{-6}	16.2 (4.6 – 62.4)	
Singaporean	Case (SJS only): 6/6 (100%) ⁶			[113]
	Tolerant control: 0/8 (0%) ⁷	0.0003		[114]
	Case: 5/5 (100%) ⁸			
	Tolerant control: 1/10 (10%) ⁹		27.2 (2.7 – ∞)	[115]
	Case: 13/13 (100%) ¹⁰			
	Tolerant control: 3/26 (H.5%) ¹¹	6.9×10^{-8}	181 (8.7 – 3785)	[110]
Thai	Case (SJS only): 6/6 (100%)			
	Tolerant control: 8/42 (19%)	0.0005	25.5 (2.7 – 243)	
	Case: 37/42 (88%)			
	Tolerant control: 5/42 (12%)	2.9×10^{-12}	54.8 (14.6 – 205)	
	Case: 32/34 (94.1%)			[109]
	Tolerant control: 7/40 (17.5%)	<0.001	75.4 (13.0 – 719)	

SJS, Stevens-Johnson Syndrome.

¹ Caucasian only.

² Pediatrics. Multiple ethnicities included, please refer to the paper directly for more information.

³ All three case patients with the allele were of Asian ancestry, countries unspecified.

⁴ The one tolerant control with the allele was of Asian ancestry, country unspecified.

⁵ Four patients with *15:02 were of Asian ancestry (Vietnam, China, Cambodia and Reunion Island). Remaining 8 patients without *15:02 were Caucasian (Germany, France)

⁶ Four Malaysian, two Chinese.

⁷ Six Malaysian, two Chinese.

⁸ Pediatrics. Two Chinese, three Malaysian

⁹ Pediatrics. Seven Chinese, two Malaysian, one Indian

¹⁰ 10 Chinese, three Malaysian

¹¹ 20 Chinese, six Malaysian

Table 5
Summary of phenytoin and *15:02 pharmacogenetic studies

p-values and odds ratios (ORs) listed pertain to the risk for phenytoin-induced Stevens-Johnson Syndrome (SJS) or toxic epidermal necrolysis (TEN) in patients carrying the *15:02 allele as compared to non-carriers. p-values and ORs were calculated by comparing the frequency of *15:02 for patients who developed SJS/TEN to the frequency in phenytoin-tolerant controls. Prevalence of *15:02 is listed in patients who developed SJS/TEN (case) and in those who were phenytoin-tolerant (tolerant control). An interactive version of this table is available online at <http://www.pharmgkb.org/haplotype/PA165954769>, and is updated as new results come to our attention.

Population	*15:02 prevalence	p-value	Odds ratio (95% CI)	Ref
Han Chinese	Case (SJS/TEN): 7/15 (46.7%)			[130]
	Tolerant control: 15/75 (20%)	0.045	3.5 (1.1 – 11.2)	
	Case (SJS/TEN): 8/26 (30.8%)			[131]
	Tolerant controls: 9/113 (8%)	0.0041	5.1 (1.8 – 15.1)	
	Case (SJS): 1/2 (50%)			[132]
	Combined case (SJS/TEN) ¹ : 10/29 (35%)			
	Tolerant control: 9/113 (8%)	0.001 ²	6.1 (2.2 – 17.0)	
	Case (SJS/TEN): 13/48 (27.1%)	0.025 ³	5.0 (2.0 – 13)	[133]
	Tolerant control: 9/130 (6.9%)			
Thai	Case (SJS): 4/4 (100%)			[110]
	Tolerant controls: 0/7 (0%)	0.005	18.5 (1.8 – 188)	
	Case (SCARs): 1/17 (5.88%)	0.35	0.35 (0.03 – 3.9)	[134]
	Tolerant control: 3/17 (17.6%)			

¹ Combined study results from [90,111,130].

² p-value for comparison in *15:02 frequencies between tolerant controls and combined cases.

³ Bonferroni-corrected p-value.